Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer

by Maria E. Cabanillas, Mimi I. Hu, Jean-Bernard Durand, Naifa L. Busaidy
Published 2011-01-01

Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; referees: 3 approved]

by Maria E. Cabanillas, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, Ramona Dadu, Neil Gross, G. Brandon Gunn, Heath Skinner, Gilbert Cote, Horiana B. Grosu, Priyanka Iyer, Naifa L. Busaidy
Published 2018-01-01

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

by Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross, Maria E. Cabanillas
Published 2018-07-01

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

by Jessica Lee, Vivek Subbiah, Shuang Liu, Jason Roszik, David Hong, Funda Meric-Bernstam, John Heymach, Ramona Dadu, Kenneth Hess, Le Huang, Aparna Hegde, Alexander Y Andreev-Drakhlin, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Elizabeth G Grubbs, Siraj M Ali, Yasir Y Elamin, George R Simon, George R Blumenschein, Jr, Vassiliki A Papadimitrakopoulou
Published 2020-10-01